Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation

The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors

(2013) Stephen P.H. Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12DMouse Model

(2012) Belinda Gier et al.   DIABETES

Direct Control of Brown Adipose Tissue Thermogenesis by Central Nervous System Glucagon-Like Peptide-1 Receptor Signaling

(2012) S. H. Lockie et al.   DIABETES

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial

(2012) J. Rosenstock et al.   DIABETES CARE

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

(2012) G. Grunberger et al.   DIABETIC MEDICINE

Direct effect of GLP-1 infusion on endogenous glucose production in humans

(2012) M. Seghieri et al.   DIABETOLOGIA

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice

(2012) Naim Panjwani et al.   ENDOCRINOLOGY

Unraveling oxyntomodulin, GLP1's enigmatic brother

(2012) Alessandro Pocai   JOURNAL OF ENDOCRINOLOGY

Glucagon-like peptide-1 of brainstem origin activates dorsomedial hypothalamic neurons in satiated rats

(2012) E. Renner et al.   PEPTIDES

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor

(2012) Aiying Wang et al.   BMC Pharmacology & Toxicology

Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice

(2011) Melissa A. Burmeister et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Consequences of splice variation on Secretin family G protein-coupled receptor function

(2011) Sebastian GB Furness et al.   BRITISH JOURNAL OF PHARMACOLOGY

Snapin Mediates Incretin Action and Augments Glucose-Dependent Insulin Secretion

(2011) Woo-Jin Song et al.   Cell Metabolism

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans

(2011) M. A. Nauck et al.   DIABETES

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

(2011) A.J. Scheen   DIABETES & METABOLISM

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study

(2011) J. K. Berg et al.   DIABETES OBESITY & METABOLISM

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

(2011) R. R. Henry et al.   DIABETES OBESITY & METABOLISM

Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4

(2011) Scott E. Kanoski et al.   ENDOCRINOLOGY

Glucagon-Like Peptide-1 Enhances Glucokinase Activity in Pancreatic β-Cells through the Association of Epac2 with Rim2 and Rab3A

(2011) Jae-Hyung Park et al.   ENDOCRINOLOGY

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

(2011) R. Pratley et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Phospholipase C-ε links Epac2 activation to the potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans

(2011) Igor Dzhura et al.   Islets

Vagal control of pancreatic β-cell proliferation

(2010) James Lausier et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor

(2010) Martha C. Washington et al.   BRAIN RESEARCH

GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons

(2010) Kathleen J. Griffioen et al.   CARDIOVASCULAR RESEARCH

Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study

(2010) S. Arnolds et al.   DIABETES CARE

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

(2010) Wolfgang Glaesner et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase

(2010) M. Malm-Erjefalt et al.   DRUG METABOLISM AND DISPOSITION

Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor

(2010) Kiwon Ban et al.   ENDOCRINOLOGY

Glucagon-like Peptide-1 Increases β-Cell Glucose Competence and Proliferation by Translational Induction of Insulin-like Growth Factor-1 Receptor Expression

(2010) Marion Cornu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hepatic-Portal Vein Infusions of Glucagon-Like Peptide-1 Reduce Meal Size and Increase c-Fos Expression in the Nucleus Tractus Solitarii, Area Postrema and Central Nucleus of the Amygdala in Rats

(2010) I. Baumgartner et al.   JOURNAL OF NEUROENDOCRINOLOGY

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening

(2010) C. Koole et al.   MOLECULAR PHARMACOLOGY

Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats

(2009) Jason G. Barrera et al.   DIABETES

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

(2009) J. Rosenstock et al.   DIABETES CARE

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

(2009) J. S. Nachnani et al.   DIABETOLOGIA

GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a β-Arrestin 1-mediated ERK1/2 Activation in Pancreatic β-Cells

(2009) Julie Quoyer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Direct Control of Peripheral Lipid Deposition by CNS GLP-1 Receptor Signaling Is Mediated by the Sympathetic Nervous System and Blunted in Diet-Induced Obesity

(2009) R. Nogueiras et al.   JOURNAL OF NEUROSCIENCE

Vagally mediated effects of glucagon-like peptide 1:in vitroandin vivogastric actions

(2009) Gregory M. Holmes et al.   JOURNAL OF PHYSIOLOGY-LONDON

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis

(2009) Eva Tomas et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans

(2008) Adil E. Bharucha et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity

(2008) C. Cabou et al.   DIABETES

Arcuate Glucagon-Like Peptide 1 Receptors Regulate Glucose Homeostasis but Not Food Intake

(2008) D. A. Sandoval et al.   DIABETES

Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects

(2008) Haiqinq Dai et al.   DIABETES OBESITY & METABOLISM

Caudal Brainstem Processing Is Sufficient for Behavioral, Sympathetic, and Parasympathetic Responses Driven by Peripheral and Hindbrain Glucagon-Like-Peptide-1 Receptor Stimulation

(2008) Matthew R. Hayes et al.   ENDOCRINOLOGY

Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety

(2008) Diana L. Williams et al.   ENDOCRINOLOGY

Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas

(2008) Ditte Tornehave et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Pattern of Intra-Family Hetero-Oligomerization Involving the G-Protein-Coupled Secretin Receptor

(2008) Kaleeckal G. Harikumar et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Role of the cAMP sensor Epac as a determinant of KATPchannel ATP sensitivity in human pancreatic β-cells and rat INS-1 cells

(2008) Guoxin Kang et al.   JOURNAL OF PHYSIOLOGY-LONDON

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome

(2008) p. m. hellström et al.   NEUROGASTROENTEROLOGY AND MOTILITY

GLP-1 (9-36) Amide, Cleavage Product of GLP-1 (7-36) Amide, Is a Glucoregulatory Peptide

(2008) Dariush Elahi et al.   Obesity

 -Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic   cells

(2008) N. Sonoda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

(2008) Helle Linnebjerg et al.   REGULATORY PEPTIDES

The Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption

(2007) Chizumi Yamada et al.   ENDOCRINOLOGY